TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03619915

Intervention type: OTHER
Intervention: Functional Independence Measure
Description: Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.

Intervention type: OTHER
Intervention: Functional Independence Measure
Description: Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.

Intervention type: OTHER
Intervention: Functional Independence Measure
Description: Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
Study: NCT03876054

Intervention type: DEVICE
Intervention: Dorsal root ganglion stimulation (DRG)
Description: Subjects will be implanted with market-released Abbott DRG system
Study: NCT03417960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold.~In study 1, the accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. In study 2, the accelerated paradigm will consist of 12 sessions per day for 5 total treatment days. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method.
Study: NCT01844050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Description: According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03574558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Logic Switch Advisor
Description: Study algorithm will be used in order to determine the initial pump setting/ MDI dosing while switching from from MDI to pump therapy or vice versa
Study: NCT03891784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study: NCT00829673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate Hydrochloride
Description: 10 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmethylphenidate Hydrochloride
Description: 10 mg Tablet
Study: NCT06560710

Intervention type: OTHER
Intervention: vitrectimy
Description: Clinical characteristics and surgical outcomes

Intervention type: OTHER
Intervention: vitrectimy
Description: Clinical characteristics and surgical outcomes
Study: NCT02348463

Intervention type: DRUG
Intervention: Clindamycin-2-phosphate
Description: how many women will deliver before the 37th week of gestation
Study: NCT00561015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
Study: NCT03990350

Intervention type: OTHER
Intervention: Food Frequency Questionnaire
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.

Intervention type: OTHER
Intervention: Food Frequency Questionnaire
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.

Intervention type: OTHER
Intervention: Food Frequency Questionnaire
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.

Intervention type: OTHER
Intervention: 24-hour dietary recall diary
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.

Intervention type: OTHER
Intervention: 24-hour dietary recall diary
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.

Intervention type: OTHER
Intervention: 24-hour dietary recall diary
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.

Intervention type: OTHER
Intervention: 24-hour dietary recall diary
Description: At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.
Study: NCT02585128

Intervention type: OTHER
Group type: OTHER
Intervention: Delirium assessment
Description: During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)

Intervention type: OTHER
Group type: OTHER
Intervention: MMSE (Mini Mental State Examination)

Intervention type: OTHER
Group type: OTHER
Intervention: Barthel index

Intervention type: OTHER
Group type: OTHER
Intervention: HADS (Hospital Anxiety and Depression Scale)

Intervention type: OTHER
Group type: OTHER
Intervention: MNA-SF (Mini Nutritional Assessment - Short Form)

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS (Near-Infrared Spectroscopy)
Description: Regional cerebral oxygen saturation monitoring during TAVI procedure

Intervention type: OTHER
Group type: OTHER
Intervention: CIRS (Cumulative Illness Rating Scale)
Study: NCT02862275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04377386

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 200 IU D vitamin
Description: Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
Study: NCT03170921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angola
Description: The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benguela
Description: The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: São Bento
Description: The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
Study: NCT02804646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed plus cisplatin or carboplatin
Description: the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed plus cisplatin or carboplatin
Description: the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
Study: NCT01294072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin conjugated with plant exosomes
Description: tablets-taken daily for 7 days - 15 subjects
Study: NCT04084392

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bridge Clinic
Description: Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Referral to an outpatient provider for addiction treatment.
Study: NCT00509106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil for Injection
Description: 2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
Study: NCT04318574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance, Agility, Strengthening Exercise (BASE) Class
Description: The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
Study: NCT03542188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary Stroke Center (PSC)
Description: Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Stroke Center (CSC)
Description: Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Stroke Center (CSC)
Description: Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
Study: NCT04438421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid
Description: Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Study: NCT00561015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
Study: NCT00492076

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pangramin Plus D. pteronyssinus 100%
Description: 1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pangramin Plus D. pteronyssinus 100%
Description: 1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo
Study: NCT04343196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diagnostic Angiography (DSA or DVA based on randomization result)
Description: After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Angiography (DSA or DVA based on randomization result)
Description: After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
Study: NCT02441621

Intervention type: OTHER
Group type: OTHER
Intervention: passive leg raising
Description: The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.

Intervention type: OTHER
Group type: OTHER
Intervention: premedication
Description: patients receive premedication with midazolam 7.5 mg p.o.

Intervention type: OTHER
Group type: OTHER
Intervention: intubation and mechanical ventilation
Description: After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.

Intervention type: OTHER
Group type: OTHER
Intervention: central venous catheter
Description: a central venous catheter in the right or left internal jugular vein.

Intervention type: OTHER
Group type: OTHER
Intervention: arterial catheter
Description: Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter

Intervention type: OTHER
Group type: OTHER
Intervention: transesophageal echocardiography
Description: Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.

Intervention type: OTHER
Group type: OTHER
Intervention: transpulmonary thermodilution catheter
Description: In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
Study: NCT01034358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Vaccine
Description: 0.5mL intramuscular for 3 doses at 0, 2, and 6 months
Study: NCT01883713

Intervention type: DEVICE
Intervention: Brain Oximetry
Description: Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
Study: NCT01686438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia
Description: A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
Study: NCT00459420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 100-200 mg BID
Description: Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00759317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine (Effexor)
Description: Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venlafaxine (Effexor)
Description: Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.